03/28/2024
5:03 AM | Chemomab Therapeutics (Filer)
| Form 20-F
Registration statement / Annual report / Transition report | |
03/11/2024
6:19 PM | Chemomab Therapeutics (Subject)
OrbiMed Israel BioFund GP Limited Partnership (Filed by)
| Form SC 13D/A | |
03/07/2024
6:00 AM | Chemomab Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/03/2024
6:00 AM | Chemomab Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/15/2023
3:35 PM | Chemomab Therapeutics (Subject)
OrbiMed Israel BioFund GP Limited Partnership (Filed by)
| Form SC 13D/A | |
11/09/2023
7:00 AM | Chemomab Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/05/2023
11:15 PM | Chemomab Therapeutics (Filer)
| Form EFFECT | |
10/30/2023
7:33 AM | Chemomab Therapeutics (Filer)
| Form F-3/A | |
10/16/2023
3:25 PM | Chemomab Therapeutics (Filer)
| Form F-3
Registration statement for securities of certain foreign private issuers | |
08/14/2023
7:05 AM | Chemomab Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/08/2023
5:00 AM | Chemomab Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/05/2023
4:48 PM | Chemomab Therapeutics (Issuer)
Darvish Nissim (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/03/2023
2:49 PM | Chemomab Therapeutics (Filer)
| Form 6-K
Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/20/2023
5:03 AM | Chemomab Therapeutics (Issuer)
Quigley Jill M. (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/05/2023
3:54 PM | Chemomab Therapeutics (Issuer)
Fatal Sigal (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
06/05/2023
6:00 AM | Chemomab Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
05/11/2023
5:07 AM | Chemomab Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
05/11/2023
5:10 AM | Chemomab Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
